Sitagliptin protects renal glomerular endothelial cells against high glucose-induced dysfunction and injury

References

• Umanath K, Lewis JB. Update on diabetic nephropathy: core curriculum 2018. Am J Kidney Dis. 2018;71(6):884–895.
   PubMed Web of Science ®Google Scholar
• Tung CW, Hsu Y-C, Shih Y-H, et al. Glomerular mesangial cell and podocyte injuries in diabetic nephropathy. Nephrology (Carlton). 2018;23(Suppl 4):32–37.
   PubMed Web of Science ®Google Scholar
• Fu J, Lee K, Chuang PY, et al. Glomerular endothelial cell injury and cross talk in diabetic kidney disease. Am J Physiol Renal Physiol. 2015;308(4):F287–97.
   PubMed Web of Science ®Google Scholar
• Lassen E, Daehn IS. Molecular mechanisms in early diabetic kidney disease: glomerular endothelial cell dysfunction. Int J Mol Sci. 2020;21:24.
   Web of Science ®Google Scholar
• Chen SJ, Lv LL, Liu BC, et al. Crosstalk between tubular epithelial cells and glomerular endothelial cells in diabetic kidney disease. Cell Prolif. 2020;53(3):e12763.
   PubMed Web of Science ®Google Scholar
• Scott LJ. Sitagliptin: a review in type 2 diabetes. Drugs. 2017;77(2):209–224.
   PubMed Web of Science ®Google Scholar
• Goncalves A, Almeida L, Silva AP, et al. The dipeptidyl peptidase-4 (DPP-4) inhibitor sitagliptin ameliorates retinal endothelial cell dysfunction triggered by inflammation. Biomed Pharmacother. 2018;102:833–838.
   PubMed Web of Science ®Google Scholar
• Goncalves A, Marques C, Leal E, et al. Dipeptidyl peptidase-IV inhibition prevents blood-retinal barrier breakdown, inflammation and neuronal cell death in the retina of type 1 diabetic rats. Biochim Biophys Acta. 2014;1842(9):1454–1463.
   PubMed Web of Science ®Google Scholar
• Fuchigami A, Shigiyama F, Kitazawa T, et al. Efficacy of dapagliflozin versus sitagliptin on cardiometabolic risk factors in Japanese patients with type 2 diabetes: a prospective, randomized study (DIVERSITY-CVR). Cardiovasc Diabetol. 2020;19(1):1.
   PubMed Web of Science ®Google Scholar
• Yang TY, Liaw Y-P, Huang J-Y, et al. Association of sitagliptin with cardiovascular outcome in diabetic patients: a nationwide cohort study. Acta Diabetol. 2016;53(3):461–468.
   PubMed Web of Science ®Google Scholar
• Wang J, Hu L, Chen Y, et al. Sitagliptin improves renal function in diabetic nephropathy in male Sprague Dawley rats through upregulating heme oxygenase-1 expression. Endocrine. 2019;63(1):70–78.
   PubMed Web of Science ®Google Scholar
• Mega C, Teixeira-de-lemos E, Fernandes R, et al. Renoprotective effects of the dipeptidyl peptidase-4 inhibitor sitagliptin: a review in type 2 diabetes. J Diabetes Res. 2017;2017:5164292.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhou PH, Li P, et al. Long non-coding RNA H19 regulates proliferation and doxorubicin resistance in MCF-7 cells by targeting PARP1. Bioengineered. 2020;11(1):536–546.
   PubMed Web of Science ®Google Scholar
• Wang Z, Cao YY, Zhang KZ, et al. Gold nanoparticles alleviates the lipopolysaccharide-induced intestinal epithelial barrier dysfunction. Bioengineered. 2021;12(1):6472–6483.
   PubMed Web of Science ®Google Scholar
• Volpe CMO, Villar-Delfino PH, Dos Anjos PMF, et al. Cellular death, reactive oxygen species (ROS) and diabetic complications. Cell Death Dis. 2018;9(2):119.
   PubMed Web of Science ®Google Scholar
• Eftekhari A, Vahed SZ, Kavetskyy T, et al. Cell junction proteins: crossing the glomerular filtration barrier in diabetic nephropathy. Int J Biol Macromol. 2020;148:475–482.
   PubMed Web of Science ®Google Scholar
• Elmarakby AA, Sullivan JC. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther. 2012;30(1):49–59.
   PubMed Web of Science ®Google Scholar
• Sifuentes-Franco S, Padilla-Tejeda DE, Carrillo-Ibarra S, et al. Oxidative stress, apoptosis, and mitochondrial function in diabetic nephropathy. Int J Endocrinol. 2018;2018:1875870.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Guo Z, Yan W, et al. Cardiovascular effects of sitagliptin - an anti-diabetes medicine. Clin Exp Pharmacol Physiol. 2018;45(7):628–635.
   PubMed Web of Science ®Google Scholar
• Tsikas D. Assessment of lipid peroxidation by measuring malondialdehyde (MDA) and relatives in biological samples: analytical and biological challenges. Anal Biochem. 2017;524:13–30.
   PubMed Web of Science ®Google Scholar
• Wu LL, Chiou -C-C, Chang P-Y, et al. Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta. 2004;339(1–2):1–9.
   PubMed Web of Science ®Google Scholar
• Greene C, Hanley N, Campbell M. Claudin-5: gatekeeper of neurological function. Fluids Barriers CNS. 2019;16(1):3.
   PubMed Web of Science ®Google Scholar
• McConnell BB, Yang VW. Mammalian Kruppel-like factors in health and diseases. Physiol Rev. 2010;90(4):1337–1381.
   PubMed Web of Science ®Google Scholar
• Dumayne C, Tarussio D, Sanchez-Archidona AR, et al. Klf6 protects beta-cells against insulin resistance-induced dedifferentiation. Mol Metab. 2020;35:100958.
   PubMed Web of Science ®Google Scholar
• Zou XZ, Gong Z-C, Liu T, et al. Involvement of epithelial-mesenchymal transition afforded by activation of LOX-1/ TGF-beta1/KLF6 signaling pathway in diabetic pulmonary fibrosis. Pulm Pharmacol Ther. 2017;44:70–77.
   PubMed Web of Science ®Google Scholar
• Qi W, Chen X, Holian J, et al. Transcription factors Kruppel-like factor 6 and peroxisome proliferator-activated receptor-{gamma} mediate high glucose-induced thioredoxin-interacting protein. Am J Pathol. 2009;175(5):1858–1867.
   PubMed Web of Science ®Google Scholar
• Qi W, Holian J, Tan CYR, et al. The roles of Kruppel-like factor 6 and peroxisome proliferator-activated receptor-gamma in the regulation of macrophage inflammatory protein-3alpha at early onset of diabetes. Int J Biochem Cell Biol. 2011;43(3):383–392.
   PubMed Web of Science ®Google Scholar
• Karagianni F, Prakoura N, Kaltsa G, et al. Transgelin up-regulation in obstructive nephropathy. PLoS One. 2013 June 26;8(6):e66887.
   PubMed Web of Science ®Google Scholar
• Gallardo-Vara E, Blanco FJ, Roqué M, et al. Transcription factor KLF6 upregulates expression of metalloprotease MMP14 and subsequent release of soluble endoglin during vascular injury. Angiogenesis. 2016 Apr;19(2):155–171.
   PubMed Web of Science ®Google Scholar
• Remm F, Kränkel N, Lener D, et al. Sitagliptin accelerates endothelial regeneration after vascular injury independent from GLP1 receptor signaling. Stem Cells Int. 2018 Feb 8;2018:5284963.
   PubMed Web of Science ®Google Scholar
• Vicen M, Vitverova B, Havelek R, et al. Regulation and role of endoglin in cholesterol-induced endothelial and vascular dysfunction in vivo and in vitro. FASEB J. 2019;33(5):6099–6114.
   PubMed Web of Science ®Google Scholar
• Wang H, Yang G, Zhang Q, et al. Apremilast ameliorates ox-LDL-induced endothelial dysfunction mediated by KLF6. Aging (Albany NY). 2020 Oct 14;12(19):19012–19021.
   PubMedGoogle Scholar